Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Metabolon Collaborates with GSK for Metabolomics Research Platform

By BiotechDaily International staff writers
Posted on 02 Jun 2014
Print article
Metabolon, Inc. (Research Triangle Park, NC, USA), a diagnostics and research services company offering metabolomics research platforms, has entered into a collaboration with GlaxoSmithKline (GSK; London, UK) to provide metabolomic profiling services and to collaborate on other research projects utilizing Metabolon’s DiscoveryHD4 platform.

The collaboration will give GSK access to Metabolon’s bioinformatics tools in addition to the company’s proprietary disease ontologies, as well as visualization tools that will integrate metabolomics data with existing genomics and proteomics data.

John Ryals, Metabolon president and CEO, commented, “We are pleased to announce a collaboration with GSK. We believe that embedding metabolomic profiling capabilities at the various stages of R&D is important to enhance the phenotypic ‘picture’ with the aim of yielding translatable, meaningful results. Gaps of knowledge can be bridged through the understanding metabolomics provides, which could lead to better targets, higher quality molecules, faster time to the clinic, and reduced risk and cost.”

Metabolomics has conducted thousands of metabolomics studies across numerous therapeutic areas and has developed expertise in metabolic pathways and targets that are involved in the onset of disease and its progression. Metabolon’s technology platforms are known for their rapid, repeatable results. Expert, credentialed biochemists interpret biologic data to provide actionable understanding into key disease metabolic processes, drug action, and patient response.

Metabolomics is a rapidly evolving field of biochemical research and discovery focused on the measurement of small molecules involved in metabolism. Metabolon’s proprietary metabolomics technology maps these small molecule pathways to identify diseases, discover biomarkers, and better understand complex biologic processes. The company’s business uses its metabolomics technology to conduct sponsored studies for life sciences researchers in industry and academia, which provide clues into complex biochemical processes. Data from these studies are used to populate Metabolon’s large and growing metabolomic information and pathway knowledge databases, which generate new product concepts for the company’s diagnostics business.

Related Links:

Metabolon
GlaxoSmithKline



Print article

Channels

Genomics/Proteomics

view channel
Image: The first 3D map of the cancer-associated protein DCLK1 (doublecortin-like kinase 1), revealed how it functions (Photo courtesy of Walter and Eliza Hall Institute).

Kinase Domain Mutation Causes Protein Malfunction and Tumor Development

A team of chemical biologists has generated the first molecular map of the protein doublecortin kinase like domain 1 (DCLK1), a factor linked to more than 10% of gastric cancers that has also been found... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.